A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects
Phase 2
3 Years
11 Years
3 Years
11 Years
Not Enrolling
Both
Warts
Both
Warts
Trial Information
A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects
Inclusion Criteria:
- Diagnosis of common warts
- Ages between 3 to 11
Exclusion Criteria:
- Other types of wart(s), ie. plantar
- Currently participating in another clinical study
- Chronic viral hepatitis B or C
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment
Outcome Measure:
Clearance of treated wart(s)
Authority:
United States: Food and Drug Administration
Study ID:
1535-RESI
NCT ID:
NCT00116675
Start Date:
March 2005
Completion Date:
April 2006
Related Keywords:
- Warts
- Common Wart(s)
- Pediatric
- Wart(s)
- Children
- 3M Pharmaceuticals
- Resiquimod
- Warts
Name | Location |
|---|---|
| Dartmouth-Hitchcock Medical Center | Lebanon, New Hampshire 03756 |
| Children's Clinic of Jonesboro, PA | Jonesboro, Arkansas 72401 |
| University of California - San Francisco | San Francisco, California 94143 |
| Longmont Clinic/Longmont Medical Research Network | Longmont, Colorado 80501 |
| Mercy Health Research | St. Louis, Missouri 63141 |
| Rhode Island Hospital - Jane Brown Building | Providence, Rhode Island 02903 |
| DermResearch, Inc. | Austin, Texas 78759 |
| Alpine Pediatrics | Pleasant Grove, Utah 84062 |
| Walla Walla Clinic | Walla Walla, Washington 99362 |
| Advanced Healthcare | Milwaukee, Wisconsin 53209 |
